Long trade : SPPI +40% (10/17)

  

** monthly **

Spectrum Pharma reports new data for Poziotinib; demonstrates evidence of significant antitumor activity

• Co announced the oral presentation of interim data from a Phase 2 clinical study evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer
• Poziotinib demonstrates evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with interim data showing an Objective Response Rate of 73%.
• Evidence of central nervous system activity in a patient with CNS metastasis and another with leptomeningeal disease.
• On October 18th at 8:30 a.m. EDT/5:30 a.m. PDT, the Company will hold a conference call with Dr. John Heymach, from The University of Texas MD Anderson Cancer Center to discuss the study results.